Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3316-3331

  Jamieson, Nigel B ^a   Carter, C Ross ^a   McKay, Colin J ^a   Oien, Karin A ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN S 100; S100 CALCIUM BINDING PROTEIN A2; SURVIVIN; UNCLASSIFIED DRUG; UVOMORULIN;

DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

ADENOCARCINOMA; ALGORITHMS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 79956044903     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3284     Document Type: Review

References (155)

1. Office for National Statistics. National Statistics Online: cancer survival [cited 2010 Oct 7]. Available from: http://www.statistics.gov.uk/CCI/ nugget.asp?ID=861&Pos=1&ColRank=2&Rank=384.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
4. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-210.
5. Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.
6. Luttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000;191:154-61. (Pubitemid 30394893)
7. Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010;251:1003-10.
8. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
9. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22. (Pubitemid 38064035)
10. Grutzmann R, Boriss H, Ammerpohl O, Lüttges J, Kalthoff H, Schackert HK, et al. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 2005;24:5079-88. (Pubitemid 41129085)
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
12. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
13. Taylor CR. Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem 2006;81:3-12. (Pubitemid 43879085)
14. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010;23 Suppl 2:S52-9.
15. Hassan S, Ferrario C, Mamo A, Basik M. Tissue microarrays: emerging standard for biomarker validation. Curr Opin Biotechnol 2008;19:19-25. (Pubitemid 351226513)
16. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:1-11. (Pubitemid 34477366)
17. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41:2213-36. (Pubitemid 41415597)
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416-22. (Pubitemid 43115010)
19. Takagi K, Takada T, Amano H. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. J Gastroenterol 2005;40:402-8.
20. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-19. (Pubitemid 33040631)
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
24. Cochrane Collaboration [cited 2010 Feb 1]. Available from: www.cochrane.org.
25. Ikeda N, Nakajima Y, Sho M, Adachi M, Huang CL, Iki K, et al. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer 2001;92:488-99. (Pubitemid 32735183)
26. Nakamori S, Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Kameyama M, et al. Clinicopathological features and prognostic significance of nucleoside diphosphate kinase/nm23 gene product in human pancreatic exocrine neoplasms. Int J Pancreatol 1993;14:125-33.
27. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, et al. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996;2:2015-22. (Pubitemid 27006634)
28. Nio Y, Dong M, Iguchi C, Yamasawa K, Toga T, Itakura M, et al. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001;76:188-96. (Pubitemid 32240229)
29. Dang C, Zhang Y, Ma Q, Shimahara Y. Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol 2006;21:850-8. (Pubitemid 43793283)
30. Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit 2009;15:BR148-56.
31. Matsumoto K, Mizoshita T, Tsukamoto T, Ogasawara N, Hirata A, Shimizu Y, et al. Cdx2 expression in pancreatic tumors: relationship with prognosis of invasive ductal carcinomas. Oncol Rep 2004;12:1239-43.
32. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002;25:122-9. (Pubitemid 34815907)
33. Watanabe I, Hasebe T, Sasaki S, Konishi M, Inoue K, Nakagohri T, et al. Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome. Pancreas 2003;26:326-33. (Pubitemid 36529956)
34. Xie MJ, Motoo Y, Iovanna JL, Su SB, Ohtsubo K, Matsubara F, et al. Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal adenocarcinoma. Dig Dis Sci 2003;48:459-64. (Pubitemid 36324151)
35. Kong G, Kim EK, Kim WS, Lee YW, Lee JK, Paik SW, et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol 2001;29:133-40.
36. Truan N, Vizoso F, Fresno MF, Fernández R, Quintela I, Alexandre E, et al. Expression and clinical significance of pepsinogen C in resectable pancreatic cancer. Int J Biol Markers 2001;16:31-6. (Pubitemid 32243579)
37. Schoppmeyer K, Kronberg J, Tannapfel A, Mossner J, Wittekind C, Caca K. Predictive value of heparanase expression in the palliative therapy of pancreatic cancer. Pancreatology 2005;5:570-5. (Pubitemid 41407289)
38. Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956-61. (Pubitemid 39383046)
39. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-95.
40. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009;69:2950-5.
41. Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, et al. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 2000;128:520-30.
42. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009;28:2903-9.
43. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531-42. (Pubitemid 35402956)
44. Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009;137:558-68, 68 e1-11.
45. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, et al. Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg 1999;3:263-77.
46. Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, et al. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 2007;20:570-8. (Pubitemid 46631999)
47. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006;13:933-9.
48. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006; 106:1677-84.
49. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J Gastroenterol 2005;11:2744-7. (Pubitemid 40704240)
50. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, et al. High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006;32:376-81. (Pubitemid 43772193)
51. Feakins RM, Ghaffar AH. p27 Kip1 expression is reduced in pancreatic carcinoma but has limited prognostic value. Hum Pathol 2003;34:385-90. (Pubitemid 36535024)
52. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:1290-5.
53. Fong D, Hermann M, Untergasser G, Pirkebner D, Draxl A, Heitz M, et al. Dkk-3 expression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci 2009;100:1414-20.
54. Fujioka S, Yoshida K, Yanagisawa S, Kawakami M, Aoki T, Yamazaki Y. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001;92:1788-97. (Pubitemid 32952497)
55. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, et al. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 2004;11:277-84.
56. Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053-8. (Pubitemid 38495828)
57. Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, et al. Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas 2001;22:341-7. (Pubitemid 32402082)
58. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, et al. Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:2864-71.
59. Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y, et al. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002;99:418-23. (Pubitemid 34495856)
60. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003;9:4165-71. (Pubitemid 37204035)
61. Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L, et al. Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther 2005;4:596-601. (Pubitemid 41351236)
62. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-63. (Pubitemid 29116820)
63. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003;9:1503-8. (Pubitemid 36418408)
64. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25. (Pubitemid 350003021)
65. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:1648-52.
66. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006;59:382-6.
67. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C. Syndecan-1 expression-a novel prognostic marker in pancreatic cancer. Oncology 2005;68:97-106. (Pubitemid 41158964)
68. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, et al. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004;136:443-8. (Pubitemid 39037686)
69. Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008;32:188-96. (Pubitemid 351172132)
70. Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008;14:5348-56.
71. Koizumi M, Doi R, Toyoda E, Masui T, Tulachan SS, Kawaguchi Y, et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003;134:260-6. (Pubitemid 37070347)
72. Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, et al. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 2009;100:1243-7.
73. Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, et al. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 2006;12:6444-51. (Pubitemid 44799717)
74. Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008;14:7043-9.
75. Liau SS, Rocha F, Matros E, Redston M, Whang E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008;113:302-14.
76. Linder S, Blasjo M, von Rosen A, Parrado C, Falkmer UG, Falkmer S. Pattern of distribution and prognostic value of angiogenesis in pancreatic duct carcinoma: a semiquantitative immunohistochemical study of 45 patients. Pancreas 2001;22:240-7. (Pubitemid 32242488)
77. Lu CD, Morita S, Ishibashi T, Hara H, Isozaki H, Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999;85:1250-60. (Pubitemid 29125077)
78. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 2007;97:405-11. (Pubitemid 47196750)
79. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008;98:1389-97. (Pubitemid 351543575)
80. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 2006;97:98-108. (Pubitemid 43050182)
81. Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009;100:1444-51.
82. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009;15:2913-9.
83. Matros E, Bailey G, Clancy T, Zinner M, Ashley S, Whang E, et al. Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer 2006;106:693-702. (Pubitemid 43157634)
84. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007;6:1569-75. (Pubitemid 351590328)
85. Murphy NC, Scarlett CJ, Kench JG, Sum EY, Segara D, Colvin EK, et al. Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. Br J Cancer 2008;98:537-41. (Pubitemid 351214516)
86. Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, et al. Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 2009;28:9.
87. Nagata S, Jin YF, Yoshizato K, Tomoeda M, Song M, Iizuka N, et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009;16:2531-8.
88. Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, et al. LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia 2009;11:712-9.
89. Nio Y, Dong M, Uegaki K, Hirahara N, Minari Y, Sasaki S, et al. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas 1999;18:117-26. (Pubitemid 29180107)
90. Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T, et al. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 2001;22:230-9. (Pubitemid 32242487)
91. Nio Y, Toga T, Maruyama R, Fukushima M. Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep 2007;18:59-64.
92. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-9. (Pubitemid 40569450)
93. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-7. (Pubitemid 46649885)
94. Oida Y, Yamazaki H, Tobita K, Mukai M, Ohtani Y, Miyazaki N, et al. Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol Rep 2006;16:457-63.
95. Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol 2009;24:175-85.
96. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005;58:845-52. (Pubitemid 41113392)
97. Sasada T, Azuma K, Hirai T, Hashida H, Kanai M, Yanagawa T, et al. Prognostic significance of the immediate early response gene X-1 (IEX-1) expression in pancreatic cancer. Ann Surg Oncol 2008;15:609-17.
98. Sawai H, Funahashi H, Yamamoto M, Okada Y, Hayakawa T, Tanaka M, et al. Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003;65:167-73.
99. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. BMC Cell Biol 2006;7:8.
100. Segara D, Biankin AV, Kench JG, Langusch CC, Dawson AC, Skalicky DA, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005;11:3587-96. (Pubitemid 40627916)
101. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, et al. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002;8:2570-5. (Pubitemid 34856341)
102. Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol 2003;21:659-67. (Pubitemid 46621900)
103. Skalicky DA, Kench JG, Segara D, Coleman MJ, Sutherland RL, Henshall SM, et al. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1941-7. (Pubitemid 44664272)
104. Smith R, Xue A, Gill A, Scarlett C, Saxby A, Clarkson A, et al. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma. World J Surg 2007;31:493-502. (Pubitemid 46356075)
105. Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T, Huang KJ, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 2007;30:1359-67.
106. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87:1140-4. (Pubitemid 35418110)
107. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M, et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 2002;94:1894-901. (Pubitemid 34241129)
108. Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K, Itakura M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 2002;13:75-85. (Pubitemid 34169530)
109. Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, Asakura H, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 2003;94:425-30. (Pubitemid 36790474)
110. Takano S, Togawa A, Yoshitomi H, Shida T, Kimura F, Shimizu H, et al. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol 2008;15:3157-68.
111. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-21. (Pubitemid 34044636)
112. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000;6:4764-7. (Pubitemid 32110417)
113. Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 2005;92:2225-32. (Pubitemid 40966261)
114. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004;64:3533-7. (Pubitemid 38657928)
115. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006;12:6043-8. (Pubitemid 44703767)
116. Vimalachandran D, Greenhalf W, Thompson C, Lüttges J, Prime W, Campbell F, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005;65:3218-25. (Pubitemid 40524604)
117. Wang P, Fan J, Chen Z, Meng ZQ, Luo JM, Lin JH, et al. Low-level expression of Smad7 correlates with lymph node metastasis and poor prognosis in patients with pancreatic cancer. Ann Surg Oncol 2009;16:826-35.
118. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97:523-30. (Pubitemid 47258447)
119. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;19:1118-27. (Pubitemid 32176289)
120. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:2846-50. (Pubitemid 38509164)
121. Yamamoto S, Tomita Y, Hoshida Y, Nagano H, Dono K, Umeshita K, et al. Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol 2004;11:165-72.
122. Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005;140:1184-90.
123. Yamasawa K, Nio Y, Dong M, Yamaguchi K, Itakura M. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002;8:2563-9. (Pubitemid 34856340)
124. Karayiannakis AJ, Syrigos KN, Polychronidis A, Simopoulos C. Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 2001;21:4127-34. (Pubitemid 34229299)
125. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced membranous and ectopic cytoplasmic expression of B-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194-7. (Pubitemid 32477236)
126. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-45. (Pubitemid 38509163)
127. Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-95. (Pubitemid 27051054)
128. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 2003;9:4935-43. (Pubitemid 37323300)
129. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-7.
130. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008;34:357-64. (Pubitemid 351381290)
131. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 2006;23:74-9. (Pubitemid 44174844)
132. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
133. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18:4613-9. (Pubitemid 29042032)
134. Kimura W, Ma J, Takeshita A, Yamamoto T, Moriya T, Hirai I, et al. Analysis of c-kit protein expression in pancreatic neoplasms and its implication
135. Nio Y, Omori H, Hashimoto K, Itakura M, Koike M, Yano S, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res 2005;25:3523-9. (Pubitemid 41105235)
136. Potti A, Ganti AK, Tendulkar K, Chitajallu S, Sholes K, Koch M, et al. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003;23:2671-4. (Pubitemid 36897142)
137. Tao J, Xiong J, Li T, Yang Z, Li X, Li K, et al. Correlation between protein expression of PTEN in human pancreatic cancer and the proliferation, infiltration, metastasis and prognosis. J Huazhong Univ Sci Technolog Med Sci 2006;26:444-7.
138. Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 2005;11:2117-23.
139. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002;15:462-9. (Pubitemid 34326956)
140. Smeenk HG, Erdmann J, van Dekken H, van Marion R, Hop WC, Jeekel J, et al. Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig Surg 2007;24:38-45. (Pubitemid 46625213)
141. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76. (Pubitemid 36808651)
142. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T, et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007;2:e1155.
143. Doucas H, Mann CD, Sutton CD, Garcea G, Neal CP, Berry DP, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol 2008;97:63-8.
144. Quint K, Stintzing S, Alinger B, Hauser-Kronberger C, Dietze O, Gahr S, et al. The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 2009;9:116-26.
145. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9. (Pubitemid 27351115)
146. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-7.
147. Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Automated analysis of tissue microarrays. Methods Mol Biol 2010;664:151-62.
148. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
149. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-83.
150. Roskoski R, Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213.
151. Lee MA, Park GS, Lee HJ, Jung JH, Kang JH, Hong YS, et al. Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 2005;5:127.
152. Rückert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer 2008;99:1484-92.
153. Godfrey EM, Rushbrook SM, Carrol NR. Endoscopic ultrasound: a review of current diagnostic and therapeutic applications. Postgrad Med J 2010;86:346-53.
154. Giorgadze TA, Peterman H, Baloch ZW, Furth EE, Pasha T, Shiina N, et al. Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation. Cancer 2006;108:186-97.
155. Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008;36:200-6.